ASX CODE: OCC
Orthocell’s latest pre-clinical study underlines CelGro performance in nerve repair
Orthocell (ASX: OCC) published yet another batch of trial results relating to CelGro which it says validates its claim that the technique can deliver...
Orthocell’s CelGro bone regeneration device accelerates dental implant treatment timeframes, cuts costs
Orthocell (ASX: OCC) has achieved a substantial reduction in dental implant treatment timeframes during a study using its CelGro regeneration device which facilitates bone...
Orthocell unveils first clinical trial results for nerve regeneration platform CelGro
Regenerative medicine company Orthocell (ASX: OCC) has provided the first batch of evidence supporting the efficacy of its CelGro nerve regeneration platform.
The company published...
Orthocell hails high success rate for tendon injury treatment
Regenerative medicine company Orthocell (ASX: OCC) has announced results from a recent study that shows an 82% success rate using its novel stem cell...
Orthocell highlights its novel ability to treat tennis elbow
Regenerative medicine company Orthocell (ASX: OCC) has posted positive results from a study into its novel tendon cell therapy treatment for tennis elbow.
Orthocell says...
Orthocell looks forward to strong European market after successful clinical study
Emerging biotech company Orthocell (ASX: OCC) has received positive news regarding its CelGro medical device that improves dental bone regeneration.
The clinical study was performed...
Orthocell secures Canadian patent rights for tendon regeneration
Biotechnology focusing on regenerative medicine is making huge strides and setting foot in more countries around the world, this time courtesy of Orthocell (ASX:...
